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Abstract
Background: We present our experience with optimization and diagnostic use of quantitative real‑time polymerase chain reaction (PCR)
targeting the lytA gene of Streptococcus pneumoniae for the detection of S. pneumoniae in whole blood of children <5 years of age. The assay
was optimized to detect ≥5 CFU/10 µl or 1 copy of DNA/2 µl of blood. Methods: This assay was applied on 1912 whole blood specimens
collected from children <5 years of age with pneumonia, of which 35 specimens were lytA positive. The bacterial loads were determined through
categorization of load into five different categories, i.e., very high load, high load, moderate load, low load, and very low load. Results: Of
the 35 lytA‑positive samples, 9 (25.71%), 4 (11.42%), 1 (2.85%), 13 (37.14%), and 8 (22.85%) were categorized as very high load, high load,
moderate load, low load, and very low load, respectively. Extracted samples were also subjected to serotyping by the Centers for Disease Control
and Prevention PCR scheme. Positive samples with very high load and high load category were serotyped successfully in all instances. A high
proportion of samples with low and very low load (61.53% and 75%, respectively) remained untypeable by the currently proposed schemes.
Conclusions: LytA PCR assay in whole blood provides rapid and sensitive results for the diagnosis of invasive S. pneumoniae disease in a
resource‑limited setting, while also being amenable to quantitation and serotyping.
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Introduction
Streptococcus pneumoniae is a major cause of childhood
morbidity and mortality globally.[1] Invasive pneumococcal
disease (IPD) and pneumococcal pneumonia in children
are now considered preventable illnesses following the
introduction of pneumococcal conjugate vaccines (PCVs),
but reduction in the rates of IPD incidences highly depends
on vaccine serotype proportions causing disease.[2]
Laboratory diagnosis of IPD by conventional culture and
serological methods has several limitations including but
not limited to low sensitivity due to prior antibiotic use and
fastidiousness of the organism, longer turnaround time (TAT),
and requirement of larger volumes of blood. [3] Hence,
improved molecular diagnostic methods (e.g., polymerase
chain reaction [PCR]) of targeting the S. pneumoniae
virulence genes (psaA, ply, pbp, lytA) have been increasingly
used. [4‑8] More recently, probe‑based real‑time PCR has
Access this article online
Quick Response Code:

Website:
www.bmbtrj.org

DOI:
10.4103/bbrj.bbrj_26_17

been developed with rapid TAT, increased sensitivity, and
multiplexing capability.[9,10] lytA gene has shown greater
utility and increased sensitivity.[11,12] However, the detection
of S. pneumoniae in blood through real‑time PCR has its
own limitations such as presence of inhibitors in blood and
potential cross‑reactivity (Streptococcus mitis is known
to harbor low quantities of lytA and ply genes) as reported
by several authors.[13‑17] Owing to limitations described in
literature, this assay has not been widely adopted for routine
use in the diagnosis of IPD.
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We optimized a quantitative lytA gene real‑time PCR in
whole blood and applied it to a large number of whole blood
samples from children with pneumonia in a low‑resource
setting where routine diagnosis through blood cultures is
not possible. We also assessed the impact of this assay on
serotyping of S. pneumoniae. Our secondary aim was to
compare this quantitative lytA gene real‑time PCR with a rapid
immunochromatography testing (ICT‑BINAXNOW®) that we
conducted on a subset of samples.

Methods
Generation of standard curve and lytA assay optimizations

Standard curve was generated by setting up 10‑fold
serial dilutions of S. pneumoniae ATCC 49619 and
suspending in healthy donor’s ethylenediaminetetraacetic
acid (EDTA) blood to achieve final concentrations of
5 × 10 6 –5 × 10 2 CFUs/mL. In brief, serial dilutions
of S. pneumoniae ATCC 49619 0.5 McFarland (McF)
suspension were prepared in 3 ml of phosphate‑buffered
saline. 190 µl of EDTA blood was spiked with 10 µl of each
dilution. To verify assay specificity, blood was also spiked
with 0.5 McF suspensions of S. viridans with a 5 × 106
CFU/ml. DNA was extracted and followed by lytA real‑time
PCR, as described below [Supplementary Table 1]. Standard
curve was generated by plotting the CFU/mL concentrations
against the cycle threshold (Ct) values of spiked samples.

Data sources

The optimization and routine use were carried out as
part of the pneumococcal conjugate vaccine impact
study, which is being conducted in five districts of Sindh
province in Pakistan.[18] The study was approved by the
Aga Khan University Ethical Review Committee (ERC
no. 2818‑PED‑ERC‑13). Whole blood samples (n = 1912)
from children aged <5 years with pneumonia, meeting the
WHO criteria,[19] were collected, after obtaining written
informed consent from parents or guardians of children.
Two milliliters of blood was collected in EDTA tubes. lytA
PCR was performed for the identification of S. pneumoniae
as described below. Blood specimens that were positive
for S. pneumoniae lytA gene were further serotyped by
sequential multiplex conventional or real‑time PCR.
A subset (n = 1271) of blood specimens were also tested
with pneumococcal ICT‑BINAXNOW ® testing, as per
manufacturer’s instructions for urine samples.

DNA extraction from whole blood

Prelysis of blood samples was carried out by treating
200 µl of well‑mixed whole blood with 3 µl of 2500U/ml
mutanolysin, 20 µl lysozyme (200 mg/ml), 13.5 µl lysostaphin
(1.5 mg/ml), and 65 µl TE buffer (pH 8), incubating at
37°C for 30 min, followed by the DNA extraction using
QIAamp DNA Blood Mini kit (QIAGEN Inc., Valencia,
California, USA.) according to manufacturer’s instructions
(spin protocol). DNA was archived at −20°C, until further
processing.
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Real‑time monoplex lytA polymerase chain reaction for
the identification of Streptococcus pneumoniae in blood

Real‑time monoplex lytA PCR was carried out by targeting lytA
gene, as described by Carvalho Mda et al. in 2007.[20] In brief,
a 25 µl PCR reaction mixture was prepared by adding 12.5 µl
of TaqMan® Universal PCR Master Mix (Applied Biosystems®,
Life Technologies, USA), 1 µl of each forward and reverse
lytA primer (10 µM), 0.15 µl of lytA probe (5 µM), 6.35 µl of
molecular biology grade nuclease‑free water, and finally, 2 µl
of template DNA added to the mixture. Thermal cycling was
performed, using cycling conditions: 50°C for 2 min, 95°C
for 10 min, followed by 50 cycles at 95°C for 15 s and 60°C
for 1 min, reaction was set up in Corbett Rotor‑Gene 6000
thermal‑cycler (Corbett Life Science, USA). A Ct cutoff ≤35
was set for positive specimens. The assay was optimized to
detect 500 CFU/ml of S. pneumoniae in 200 µL of whole blood,
based on standard curve data.

RNAse P gene monoplex real‑time polymerase chain
reaction assay used as internal positive control reaction

RNAse P gene monoplex real‑time PCR was performed
independently on every specimen as an internal positive control
reaction, to rule out the presence of any inhibitors and false
negativity.[21]

Pneumococcal serotyping by sequential multiplex
conventional/real‑time polymerase chain reaction
S. pneumoniae serotyping of those blood samples with lytA
Ct value ≥30 was performed by triplex sequential real‑time
PCR as described by Pimenta et al.[22] In brief, 21 primer
pairs were grouped into seven triplex reactions for covering
37 serogroups/serotypes. PCR was carried out in reaction
mixture volumes of 25 µl, using Invitrogen‑Platinum
Quantitative PCR SuperMix‑UDG kit (Invitrogen, USA), with
10 µM primers and probes. Amplification was performed on
Applied Biosystems® 7500 real‑time PCR system (Applied
Biosystems®, Life Technologies, USA).

Blood specimens with lytA Ct value ≤30 were subjected to
conventional multiplex PCR serotyping as previously carried
out by Pai et al.[23] In brief, eight multiplex PCR reactions,
including 39 primer pairs to cover 68 serogroups/serotypes
were performed. The primer for the conserved pneumococcal
polysaccharide capsule gene (cpsA) was added as control
with each multiplex reaction. PCR was carried out in reaction
mixture volumes of 25 µl with 25 µM primers and 2X multiplex
Master Mix (Qiagen Cat# 206145, Germany). Amplification
was performed in Eppendorf Master Cycler (Eppendorf,
Hamburg, Germany). PCR products were electrophoresed on
to 2% agarose gel stained with SYBR® Green (Sigma, USA)
and visualized under ultraviolet light (GEL‑DOC Biorad Inc.,
USA).

Immunochromatography‑BINAXNOW® testing

A subset of blood specimens (n = 1271) were also subjected to
ICT‑BINAXNOW® S. pneumoniae kit testing (Alere, Hague, the
Netherlands) as per manufacturer’s instructions for urine samples.
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In brief, a swab was dipped into a whole sample and then inserted
into the test device. Three drops of reagent‑A solution were added
and results were recorded after 15 min. The test was interpreted
as positive if both sample and control lines were present, while
interpreted as negative if only the control line was present.

Results
Standard curve data

Standard curve showed a linear relationship between Ct values
and CFU/ml, DNA copies/2 µl of the sample [Figure 1]. The
limit of detection for the assay was 5 CFU/10 µl, equivalent to
1 copy of DNA/2 µl of the sample. The analytical sensitivity
of the assay was found to be 500 CFU/ml of S. pneumoniae
in 200 µl of blood. Blood samples spiked with S. viridans
were negative for lytA quantitative real‑time PCR, showing
no cross‑reactivity [Supplementary Table 1].

Result interpretation and quality control

A clinical whole blood specimen was considered positive for
S. pneumoniae when lytA PCR yielded a Ct value ≤35, and
the internal control human RNASeP gene was positive at a Ct
value of ≤35. PCR‑negative control and extraction‑negative
control yielded no Ct value and remained negative.

lytA quantitative real‑time polymerase chain reaction
assay results

A total of 1912 blood specimens were subjected to lytA
quantitative real‑time PCR results, of which 35 specimens

(1.83%) were found positive. On the basis of standard curve
data, five categories with respect to bacterial load were made,
i.e., very high load (i.e., >5 × 106 CFU/ml), high load (between
5 × 10 5 and 5 × 10 6 CFU/ml), moderate load (between
5 × 104 and 5 × 105 CFU/ml), low load (between 5 × 103
and 5 × 104 CFU/ml), and very low load (between 5 × 102
and 5 × 103 CFU/ml). Of the 35 lytA positives, 9 (25.71%),
4 (11.42%), 1 (2.85%), 13 (37.14%), and 8 (22.85%) were
categorized as very high load, high load, moderate load, low
load, and very low load, respectively.

Correlation with serotyping results and
Immunochromatography‑BINAXNOW®

Table 1 shows the correlation between lytA real‑time
PCR quantification with pneumococcal serotypes and
ICT‑BINAXNOW®.
All specimens with either very high load or high load
were successfully serotyped. However, a large proportion
of the samples with low load to very low load remained
untypeable by the serotypes included in the schemes. One
outlier in the moderate load category also remained untypeable.
The overall percentage agreement between ICT‑BINAXNOW®
and quantitative lytA real‑time PCR was found to be
98.74%, while positive percentage agreement and
negative percentage agreement were 48.38% and 100%,
respectively [Supplementary Table 2]. The lowest detectable
limit for a positive ICT‑BINAXNOW® was determined to be
between 5 × 102 and 5 × 103 CFU/ml.

Discussion
Advancement in nucleic acid detection techniques, particularly
probe‑based real‑time PCR, offers an opportunity to improve
the diagnosis of invasive S. pneumoniae disease. Detection of S.
pneumoniae is difficult, because it is fastidious, difficult to grow
due to autolysis phenomenon, and there is a limited experience
and literature available for a real‑time PCR diagnosis of IPD in
resource‑limited settings. We have successfully demonstrated
quantitative lytA real‑time PCR as well as ICT‑BINAXNOW®
in a cohort of children <5 years of age with pneumonia.
Although lytA real‑time PCR does not replace conventional
diagnosis, it offers rapid detection of S. pneumoniae in blood
and also provides valuable serotyping results which is of
paramount importance in the post‑PCV‑10 era.

Figure 1: Line graph showing the comparison of cycle threshold values
in quantitative lytA real‑time polymerase chain reaction on Y‑axis and
CFU/ml (in the upper image) or DNA copies/2 µl (in the lower image)
on X‑axis. Trend line showing a linear relationship between the cycle
threshold values and CFU/ml or DNA copies/2 µl TAC. Depicting a linear
relationship of cycle threshold values versus CFU/ml, DNA copies/2 µl
on a standard curve. CFU/ml: colonies forming unit/milliliter, DNA copies/
µl: deoxyribonucleic acid/microliter

Our study revealed that serotyping of S. pneumoniae was
dependent on bacterial load, i.e., there was no untypeable
S. pneumoniae in very high load (>5 × 106 CFU/ml) and high
load categories (between 5 × 105 CFU/ml and 5 × 106 CFU/ml),
while the proportion of untypeable results increased in lower
load categories. However, the conserved region, i.e., cpsA was
present in all the untypeable samples. Therefore, it is likely
that these samples were pneumococcal serotypes other than
those in our testing repertoire. On the contrary, it is possible
that those were truly untypeable, given the 100% success in
typing those with low Ct value for lytA, it is more likely that
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Table 1: Relationship of quantitative lytA real‑time polymerase chain reaction with immunochromatography‑BINAXNOW®
and pneumococcal serotyping
Category

Pneumococcal
load (CFU/ml)

Pneumococcal load
(DNA copies/2ul)

Very
High load

>5×106 CFU/ml

>1×104
DNA copies/2ul

Ct value
Range

lytA
positive (n)

≤23.87

9

ICT‑BINAX
Agreement with
lytA positive

Proportion
of Serotypes
Typed
Successfully
n (%)

Proportion
of Serotypes
Not Typed
(Untypeable)
n (%)

Positive=07
9 (100.00%)
Nil
Negative=02
Positive percent
agreement=77.77%
High load
Between 5×105 and
Between 1×103-1×104
23.88-27.88
4
Positive=03
4 (100.00%)
Nil
5×106 CFU/ml
DNA copies/2ul
Negative=01
Positive percent
agreement=75.00%
Moderate
Between 5×104 and
Between 1×102-1×103
27.89-31.08
1
Positive=00
Nil
1 (100.00%)
load
5×105 CFU/ml
DNA copies/2ul
Negative=01
Positive percent
agreement=0%
Low load
Between 5×103 and
Between 1×101-1×102
31.09-33.67
13
Positive=04
5 (38.46%)
8 (61.53%)
5×104 CFU/ml
DNA copies/2ul
Negative=06
Not Performed=03
Positive percent
agreement=40.00%
Very
Between 5×102 and
Between 1-1×101
33.68-36.85
8
Positive=01
2 (25.00%)
6 (75.00%)
5×103 CFU/ml
DNA copies/2ul
Low load
Negative=06
Not Performed=01
Positive percent
agreement=14.28%
A total of 1912 blood specimens were performed for lytA real‑time PCR, of which 35 were found positive for S. pneumoniae and a total of 1271 blood
specimens were processed for ICT‑BINAXNOW®, of which 15 were found positive for S. pneumoniae. PCR: Polymerase chain reaction, S. pneumoniae:
Streptococcus pneumoniae, ICT: Immunochromatography

we need more DNA copies for serotyping to work. We intend
to resolve these untypeable results through whole‑genome
sequencing in the future.

Infectious Diseases Research Laboratory staff, Project field
staff and Administration, Department of Paediatrics and Child
Health for their dedicated services and assistance.

Our study has limitations, since this was a field study, blood
cultures could not be performed and thus quantitative lytA
real‑time PCR results could not be compared with a reference
test. Furthermore, lytA PCR was not performed in blood
samples from healthy children, and therefore we could not
determine its diagnostic specificity.
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Conclusion
There is a dire need to evaluate sensitive and rapid assays for
a resource‑limited setting that can detect S. pneumoniae in
blood and will provide a strong foundation for pneumococcal
serotyping, and we have described such assay. lytA PCR assay
facilitated the diagnosis of IPD in our cohort. Once diagnostic
specificity is demonstrated in a healthy cohort of children,
this assay can be successfully used for the diagnosis of IPD
in children and can be adapted to point‑of‑care platforms to
facilitate rapid field diagnosis.
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Supplementary Table 1: Optimization of quantitative lytA real‑time polymerase chain reaction, with reference to standard
curve
S#

Dilution Preparation

Dilution

CFU/ml

CFU/10ul on SBA

CFU/ml

1

0.5 McFarland suspension of
S.pneumo in 3ml PBS
1 ml from neat +9ml PBS
1ml from 1:10+9ml PBS
1ml from 1:100+9ml PBS
1ml from 1:1000+9ml PBS
1ml from 1:10000+9ml PBS
0.5 McFarland suspension of
S.viridans in 3ml PBS

Neat

5×106 CFU/ml

50000 CFU/10ul

1:10
1:100
1:1000
1:10000
1:100000
Neat

5×105 CFU/ml
5×104 CFU/ml
5×103 CFU/ml
5×102 CFU/ml
5×101 CFU/ml
5×106 CFU/ml

5000 CFU/10ul
500 CFU/10ul
50 CFU/10ul
5 CFU/10ul
0
50000 CFU/10ul

2
3
4
5
6
7

Supplementary Table 2: Estimation of agreement between
immunochromatography‑BINAXNOW® and quantitative lytA
real‑time polymerase chain reaction
Estimation of Agreement
Quantitative lytA real‑time PCR
(Non‑reference Standard)
Positive

Negative

ICT‑BINAX (New test)
Positive
a (15)
b (0)
Negative
c (16)
d (1240)
Total
a + c (31)
b + d (1240)
*overall percent agreement=98.74% {reference formula used: 100% x
(a + d)/(a + b + c + d)}, * positive percent agreement=48.38% {reference
formula used: 100% x a/(a + c)}, * negative percent
agreement=100.00% {reference formula used: 100% x d/(b + d)}

Copies Of Pneumococcal
DNA/2ul

Ct Value

5,000,000 CFU/ml

10,000

23.88

500000 CFU/ml
50000 CFU/ml
5000 CFU/ml
500 CFU/ml
No Growth
5,000,000 CFU/ml

1000
100
10
1
0
0

27.89
31.09
33.68
36.85
Neg
Neg

